|
Recently, the m6A writer RBM15 is discovered to regulate host immune response to SARS-CoV-2 by elevating m6A modifications of multitarget genes, clinically affecting COVID-19 severity [1]. RBM15 is further proposed as a COVID-19 therapeutic target.
Fig. (A). 531 transcripts (red) were both m6A Hyper-methylated and Up-expressed in peripheral blood mononuclear cells (PBMCs) in severe but not mild COVID -19 cases on Arraystar Epitranscriptomic Microarray. (B) As analyzed by GSEA, these Hyper-Up transcripts contribute to COVID-19 severity by up-regulating programmed cell death and inflammatory response genes.
Arraystar Epitranscriptomic Microarray is the best choice to profile which transcripts are modified, the modification quantity, and the percentage of modification. The required total RNA sample amount is as little as is 3 ug, which is magnitudes lower than MeRIP-seq (> 100 ug). These superior capabilities open up opportunities for research with urgent needs and under demanding situations such as COVID-19.
For Epitranscriptomic Array service, there’s a promotion running right now thru June 30th, 2022 - Save 15% and Get Your Epitranscriptomic Profiling Done in the Right Way!
Reference
[1] Meng Y. et al (2021) RBM15-mediated N6-methyladenosine modification affects COVID-19 severity by regulating the expression of multitarget genes. Cell Death Dis 12(8):732 [PMID:34301919]
Subscribe to Our Newsletters!
|
